GH Research management commentary cites higher development costs as driver of wider operating loss in nine months ended September 2026

PUBT · 20h ago
GH Research management commentary cites higher development costs as driver of wider operating loss in nine months ended September 2026
  • GH Research management commentary reported a USD 46.56 million loss for nine months ended September 30, 2026, versus USD 34.12 million.
  • Research and development expenses rose to USD 34.85 million from USD 27.38 million, driven by technical development, clinical development and employee costs.
  • General and administrative expenses increased to USD 18.71 million from USD 16.62 million, primarily reflecting higher professional fees.
  • Third-quarter loss narrowed to USD 12.45 million from USD 14.02 million, with lower development expenses and professional fees supporting performance.
  • Cash, cash equivalents and marketable securities totaled USD 350.6 million; an April ordinary-share offering generated USD 111.2 million in net proceeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-043544), on November 13, 2026, and is solely responsible for the information contained therein.